|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Real estate properties | ||||||||||||||||||||
| Development and value-add properties | ||||||||||||||||||||
| Real estate, development and value-add properties | ||||||||||||||||||||
| Accumulated depreciation | ||||||||||||||||||||
| Real estate, net | ||||||||||||||||||||
| Real estate assets held for sale | ||||||||||||||||||||
| Unconsolidated investment | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted Cash | ||||||||||||||||||||
| Other assets, net | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| LIABILITIES AND EQUITY | ||||||||||||||||||||
| LIABILITIES | ||||||||||||||||||||
| Unsecured bank credit facilities, net of debt issuance costs | ||||||||||||||||||||
| Unsecured debt, net of debt issuance costs | ||||||||||||||||||||
| Secured debt, net of debt issuance costs | ||||||||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| EQUITY | ||||||||||||||||||||
| STOCKHOLDERS' EQUITY | ||||||||||||||||||||
| Common shares; $.0001 par value; 70,000,000 shares authorized; 53,773,403 shares issued and outstanding at September 30, 2026 and 53,348,800 at December 31, 2025 | ||||||||||||||||||||
| Excess shares; $.0001 par value; 30,000,000 shares authorized; no shares issued | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Distributions in excess of earning | ||||||||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||||||||
| Total Stockholders' Equity | ||||||||||||||||||||
| Noncontrolling interest in joint ventures | ||||||||||||||||||||
| Total Equity | ||||||||||||||||||||
| TOTAL LIABILITIES AND EQUITY | ||||||||||||||||||||
| BALANCE SHEET PARENTHETICAL DISCLOSURES | ||||||||||||||||||||
| Common shares, par value (in dollars per share) | ||||||||||||||||||||
| Total common shares, par value (in dollars per share) | ||||||||||||||||||||
| Common shares, authorized | ||||||||||||||||||||
| Total common shares, authorized | ||||||||||||||||||||
| Common shares, issued | ||||||||||||||||||||
| Total common shares, issued | ||||||||||||||||||||
| Common shares, outstanding | ||||||||||||||||||||
| Total common shares, outstanding | ||||||||||||||||||||
| Excess shares, par value | ||||||||||||||||||||
| Excess shares, authorized | ||||||||||||||||||||
| Total excess shares, authorized | ||||||||||||||||||||
| Excess Stock, Shares Issued | ||||||||||||||||||||
| Total excess Stock, Shares Issued | ||||||||||||||||||||
Loading...
